Questionnaire-based survey on chemotherapy-induced anemia

Area of Science:

• Oncology
• Hematology
• Clinical Pharmacy

Background:

• Chemotherapy-induced anemia (CIA) is a common complication in cancer patients.
• Understanding the current status of CIA and blood transfusion practices in Japan is crucial for patient care.

Purpose of the Study:

• To clarify the current status of chemotherapy-induced anemia (CIA) in Japan.
• To analyze blood transfusion rates, volumes, anemia severity, and influencing factors in cancer patients undergoing chemotherapy.

Main Methods:

• A questionnaire-based survey was conducted from September to November 2010.
• Data analyzed included chemotherapy use, blood transfusion rates and volumes, anemia severity, and factors affecting transfusion decisions across eight cancer types.
• Estimated national transfusion volumes and patient numbers with low hemoglobin levels were calculated.

Main Results:

• Anemia requiring blood transfusion occurred in 7.5% of chemotherapy patients across eight cancer types.
• An estimated 146,000 units of red blood cells are transfused annually to cancer patients with CIA in Japan.
• Many patients with hemoglobin levels below 10 g/dL did not receive transfusions, and transfusions were rarely given for hemoglobin levels above 8.0 g/dL.

Conclusions:

• Red blood cell transfusions are strictly restricted for cancer patients with CIA in Japan.
• There is a significant need for alternative therapies, such as erythropoiesis-stimulating agents, to manage CIA.
• Alternative therapies can help increase hemoglobin levels and improve the quality of life for cancer patients experiencing CIA.